Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease

Fig. 3

Unadjusted Kaplan-Meier estimates of time to mortality among diabetic patients in chronic obstructive pulmonary disease according to metformin use (N = 511). The mean follow-up period of the patients was 21.4 months, with 10,958 person-months at risk. Patients with chronic kidney disease stage 3b or higher were excluded due to concerns for confounding

Back to article page